Autoinflammatory diseases are a group of conditions in which the body’s innate immune system fires up inflammation on its own, without the provocation of an infection or the autoantibody-driven attacks seen in classic autoimmune diseases. They are driven primarily by misfiring danger sensors and overproduction of inflammatory signaling molecules, and the discovery of their genetic roots over the past two decades has reshaped how doctors think about unexplained fevers, rashes, and organ damage. The category keeps expanding as researchers identify new genes and mechanisms, and the distinction between autoinflammatory and autoimmune disease turns out to be less of a bright line than a spectrum.
What Makes Autoinflammatory Disease Different from Autoimmune Disease
The traditional split is straightforward. Autoimmune diseases like lupus and rheumatoid arthritis involve the adaptive immune system, which is the branch that learns to recognize specific targets and generates antibodies or killer T cells against the body’s own tissues. Autoinflammatory diseases, by contrast, arise from the innate immune system, the older, less targeted first line of defense. In autoinflammatory conditions, inflammation appears without high levels of autoantibodies or antigen-specific T cells.1Europe PMC. Systemic autoinflammatory disorders: autoinflammatory and autoimmune disorders The immune system behaves as though it is constantly detecting danger signals, even when none are present.
In practice, the boundary is blurry. Some conditions have features of both, and researchers now describe a spectrum with purely autoinflammatory diseases at one end and classic autoimmune diseases at the other. Adult-onset Still’s disease, for instance, involves innate immune activation with macrophage and neutrophil overactivity but can also feature some adaptive immune involvement. What unites the autoinflammatory end of the spectrum is a set of molecular mechanisms centered on structures called inflammasomes and on a handful of inflammatory signaling molecules, especially interleukin-1β.
The Inflammasome at the Center
Most autoinflammatory diseases trace back, directly or indirectly, to inflammasomes. These are molecular complexes inside immune cells that act as alarm systems. When they detect signs of damage or infection, they activate an enzyme called caspase-1, which in turn processes raw forms of inflammatory signaling molecules into their active versions, particularly interleukin-1β (IL-1β) and interleukin-18 (IL-18). In a healthy person, this process is tightly regulated. In someone with an autoinflammatory disease, the alarm is stuck in the “on” position.
The best-studied inflammasome in this context is the NLRP3 inflammasome. Gain-of-function mutations in the NLRP3 gene cause the inflammasome to activate spontaneously, flooding the body with IL-1β and triggering a form of inflammatory cell death called pyroptosis.2PubMed Central. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies This overactivation drives the symptoms of cryopyrin-associated periodic syndrome (CAPS), but the same basic principle, too much inflammasome activity leading to too much IL-1β, operates in many other autoinflammatory conditions.
In polygenic conditions like adult-onset Still’s disease, the picture is more complex. Damage-associated molecular patterns and pathogen-associated molecular patterns stimulate macrophages and neutrophils through toll-like receptors, which then activate inflammasomes. The resulting overproduction of IL-1β and IL-18 triggers cascading waves of other inflammatory signals including IL-6, TNF-α, and IL-17.3PubMed Central. Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach The inflammation feeds itself, with each round of cytokine release recruiting more immune cells and provoking further activation.
The Major Monogenic Syndromes
The conditions that first defined the autoinflammatory category are caused by single-gene mutations. Each has a distinct genetic cause, but they share overlapping features: episodic fevers, systemic inflammation, and elevated inflammatory markers in the blood.
Familial Mediterranean Fever
Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory disease, concentrated in populations of Mediterranean descent. It results from mutations in the MEFV gene, which encodes a protein called pyrin. Pyrin normally helps regulate the inflammasome. When it is mutated, immune cells become hypersensitive. Mouse studies showed that a truncated pyrin molecule, similar to what FMF patients carry, leads to exaggerated responses to bacterial components, with macrophages producing elevated levels of activated caspase-1 and mature IL-1β.4Molecular Cell. Targeted Disruption of Pyrin, the FMF Protein, Causes Heightened Sensitivity to Endotoxin and a Defect in Macrophage Apoptosis The result is attacks of fever, abdominal pain from inflamed peritoneum, chest pain from pleuritis, and painful joint swelling, typically lasting one to three days before resolving on their own, only to recur weeks or months later.
Cryopyrin-Associated Periodic Syndrome
CAPS is actually a spectrum of three conditions of increasing severity, all caused by gain-of-function mutations in NLRP3. At the mild end, patients experience cold-triggered hives and fevers. At the severe end, a condition called NOMID (neonatal-onset multisystem inflammatory disease) can cause brain inflammation, hearing loss, and bone deformities starting in infancy. The mutations cause the NLRP3 inflammasome to activate without the usual triggering signals, leading to uncontrolled release of IL-1β.5PubMed Central. CAPS and NLRP3 Researchers have shown that specific splice variants of the mutated NLRP3 protein can form active inflammasome complexes spontaneously, while other splice variants that lack certain exons cannot.6Journal of Allergy and Clinical Immunology. NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome
TRAPS
TNF receptor-associated periodic syndrome takes a different path to the same destination. Here, the mutations affect the gene for TNF receptor 1, a protein that sits on cell surfaces and binds the inflammatory molecule TNF. In TRAPS, the mutant receptor misfolds and gets trapped inside the cell’s endoplasmic reticulum instead of reaching the surface.7PubMed Central. Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome This mislocalization triggers stress responses within the cell, including production of reactive oxygen species and impaired autophagy, the cellular cleanup process that normally clears misfolded proteins.8PubMed. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases TRAPS flares tend to last longer than FMF attacks, sometimes stretching over weeks, with fever, painful red skin patches, muscle aches, and eye inflammation.
Mevalonate Kinase Deficiency
This condition stands out because its root cause is metabolic rather than directly immunological. Mutations in the gene for mevalonate kinase, an enzyme involved in cholesterol and isoprenoid biosynthesis, reduce enzyme activity so severely that it becomes the bottleneck in the pathway.9PubMed. Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency The shortage of downstream metabolic products somehow destabilizes inflammasome regulation, causing periodic fever episodes with lymph node swelling, abdominal pain, and skin rashes. The milder form, historically called hyper-IgD syndrome, features elevated immunoglobulin D levels, while the severe form (mevalonic aciduria) can cause developmental delays and failure to thrive.
When Mutations Are Not Inherited
Until recently, most recognized autoinflammatory diseases were inherited, meaning you were born with the mutation in every cell. The discovery of VEXAS syndrome in 2020 broke that mold. VEXAS is caused by somatic mutations, changes that arise after birth in blood-forming stem cells and spread through their descendants. The mutations hit a gene called UBA1, which encodes a key enzyme in the ubiquitin system, the cell’s machinery for tagging proteins for disposal. Researchers identified the mutations in more than half of patients’ blood stem cells, concentrated in myeloid immune cells but absent from lymphocytes and skin cells.10PubMed Central. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
Because UBA1 sits on the X chromosome and the mutations are somatic, VEXAS overwhelmingly affects older men. These mutated stem cells expand clonally, skewing toward myeloid differentiation and driving systemic inflammation along with blood abnormalities like anemia and blood clots.11PubMed Central. VEXAS syndrome The condition was likely hiding in plain sight for years, diagnosed as various rheumatic or hematologic conditions before genetic testing revealed the common thread. VEXAS illustrates that autoinflammatory disease is not always something you are born with and that somatic mosaicism can drive inflammation just as powerfully as inherited mutations.
Type I Interferonopathies
Not all autoinflammatory diseases revolve around IL-1β. A growing subset involves overproduction of type I interferons, signaling molecules better known for their role in antiviral defense. Conditions like CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature), SAVI (STING-associated vasculopathy with onset in infancy), and Aicardi-Goutières syndrome share a hallmark: a chronically elevated interferon signature in the blood.12Annals of the Rheumatic Diseases. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS The body acts as though it is permanently fighting a viral infection, producing inflammation that damages skin, blood vessels, lungs, and the brain. Because IL-1 blockade does not address the interferon pathway, these conditions require different treatment strategies.
The Diagnostic Challenge
Diagnosing an autoinflammatory disease can take years. The conditions are rare individually, many doctors have never encountered them, and the symptoms (recurring fevers, rashes, joint pain) overlap with infections, malignancies, and common autoimmune diseases. Fever pattern offers a clue. In a study of 210 patients with unexplained fevers, those with truly periodic fevers (regular-interval episodes) had the highest rate of confirmed autoinflammatory disease, about 70% in children and 36% in adults, while those with persistent fever that never fully resolved had a zero percent diagnostic rate for these conditions.13PubMed. Diagnostic Rate of Autoinflammatory Diseases Evaluated by Fever Patterns in Pediatric- and Adult-Onset Patients The periodicity, the fact that patients feel completely well between attacks, is a key distinguishing feature.
Genetic testing has become central to diagnosis, but it introduces its own complications. Next-generation sequencing can scan multiple genes simultaneously, which is far more efficient than older gene-by-gene methods. However, the sheer volume of variants detected makes interpretation harder.14Rheumatology. Current and future advances in genetic testing in systemic autoinflammatory diseases A variant of uncertain significance can leave clinicians in limbo. Some variants initially reported as disease-causing were later found to be common in the general population or to have minimal effect on protein function.15Annals of the Rheumatic Diseases. Guidelines for the genetic diagnosis of hereditary recurrent fevers The E148Q variant in the MEFV gene (the gene behind FMF) is a well-known example: once considered pathogenic, it is now regarded as too common and too inconsistently associated with disease to be called a clear-cut cause. Making a diagnosis still depends on the full clinical picture, not genetic results alone.
Treatment Through Cytokine Blockade
The understanding that most autoinflammatory diseases funnel through IL-1β overproduction has made IL-1-targeting drugs the backbone of treatment. Anakinra, a recombinant form of the natural IL-1 receptor antagonist, blocks the receptor for both IL-1α and IL-1β and is used across a wide range of inflammatory conditions, often off-label.16PubMed Central. Treatment of Inflammatory Diseases with IL-1 Blockade Canakinumab, a monoclonal antibody that specifically neutralizes IL-1β, has shown strong results in randomized trials across multiple autoinflammatory syndromes. In colchicine-resistant FMF patients, about 61% achieved a complete response at the standard dose, rising to roughly 71% when the dose was increased. In mevalonate kinase deficiency and TRAPS, rates reached about 57% and 73% respectively at the higher dose.17PubMed. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes For many patients, these drugs transform daily life, eliminating or drastically reducing flares that had been occurring for years.
For interferonopathies, where IL-1 blockade does not address the underlying problem, JAK inhibitors have emerged as an alternative. These small-molecule drugs block the Janus kinase enzymes that relay interferon and other cytokine signals inside cells. A systematic review covering 101 patients found that among those with type I interferonopathies, about two-thirds showed a partial response and roughly 14% achieved a complete response.18PubMed Central. Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review The responses were less dramatic than IL-1 blockade in inflammasome-driven diseases, reflecting how much harder it is to fully suppress the interferon pathway without creating vulnerability to infections. JAK inhibitors have also been tried in adult-onset Still’s disease and Behçet’s syndrome with mixed results, making them a useful second-line option rather than a universal answer.
When Inflammation Damages the Kidneys
The most feared long-term complication of poorly controlled autoinflammatory disease is AA amyloidosis. Years of chronic inflammation keep serum amyloid A (SAA) protein levels elevated, and over time, fragments of SAA misfold and deposit as amyloid fibrils in organs, especially the kidneys. The first sign is usually protein leaking into the urine, and if the underlying inflammation is not controlled, progression to kidney failure is essentially inevitable.19PubMed. Amyloidosis in autoinflammatory syndromes This is why effective suppression of inflammation matters even between flares: the damage accumulates silently. Colchicine, the first-line drug for FMF, dramatically reduced amyloidosis rates in that population. For patients who do not respond to colchicine, anti-cytokine agents can normalize SAA levels and, in some cases, reverse early amyloid deposits.20PubMed Central. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage
Why Evolution Kept These Mutations Around
It seems counterintuitive that genes causing painful, disabling inflammation would persist in human populations. For FMF, there is a compelling answer: plague. Multiple MEFV mutations are surprisingly common in Mediterranean populations, with carrier frequencies far too high to be explained by random genetic drift. Analysis of over 2,300 Turkish individuals found signatures of recent positive selection around FMF-associated mutations, suggesting they conferred a survival advantage. The mutations arose independently more than 1,800 years ago.21PubMed Central. Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis
The mechanism is elegant. Yersinia pestis, the bacterium that causes plague, injects a protein called YopM into host immune cells to suppress IL-1β production and evade the immune response. Mutant pyrin interacts less readily with YopM than normal pyrin does, meaning the bacteria’s immune-suppression trick is partially foiled. Leukocytes from FMF patients and even asymptomatic carriers released more IL-1β in response to Y. pestis than cells from unaffected people. In mouse experiments, FMF knock-in mice survived plague infection at higher rates than wild-type mice in an IL-1-dependent manner.22PubMed Central. Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis The same overactive inflammation that causes misery in peacetime was a lifesaver during plague outbreaks. Similar selective pressures may explain high carrier frequencies for other autoinflammatory mutations, though the evidence is strongest for FMF.
Pregnancy and IL-1 Blocking Therapy
For women with autoinflammatory diseases who become pregnant, a difficult question arises: is it safe to keep taking the drugs that control their inflammation? Uncontrolled flares during pregnancy carry their own risks, including premature labor and miscarriage, so stopping treatment is not always the safer option. A systematic review pooling data from 88 pregnancies exposed to anakinra or canakinumab found that about 65% resulted in healthy full-term deliveries without complications. Roughly 15% ended in preterm birth, and there was one stillbirth.23PubMed Central. A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy Those numbers are reassuring compared with the general preterm birth rate in many countries, though the sample size remains small enough that definitive safety conclusions are premature. Most rheumatologists currently recommend continuing IL-1 blockade during pregnancy when the disease is severe and uncontrolled, while monitoring closely, a pragmatic approach driven by the reality that the data, while limited, do not show a clear signal of harm.
Cellular Stress as an Inflammation Trigger
Beyond the canonical inflammasome mutations, researchers are uncovering a broader theme: cellular housekeeping failures can provoke inflammation. When proteins misfold and accumulate inside cells, a stress response called the unfolded protein response kicks in. Under normal circumstances, this response helps the cell restore order. But it can also be hijacked by inflammatory signaling pathways, including toll-like receptor signaling and mitochondrial reactive oxygen species, to amplify inflammation.24PubMed. Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond TRAPS is the clearest example of this principle in action, with its misfolded TNF receptors stuck in the endoplasmic reticulum, but the concept extends beyond any single disease. It suggests that autoinflammatory mechanisms may contribute to more common conditions where protein aggregation and chronic inflammation coexist, a connection researchers are only beginning to explore.